000308503 001__ 308503
000308503 005__ 20260219144911.0
000308503 0247_ $$2doi$$a10.1016/j.eururo.2026.01.002
000308503 0247_ $$2pmid$$apmid:41539911
000308503 0247_ $$2ISSN$$a0302-2838
000308503 0247_ $$2ISSN$$a1421-993X
000308503 0247_ $$2ISSN$$a1873-7560
000308503 037__ $$aDKFZ-2026-00143
000308503 041__ $$aEnglish
000308503 082__ $$a610
000308503 1001_ $$0P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aBenesova-Schäfer, Martina$$b0$$eFirst author$$udkfz
000308503 245__ $$aThe Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer.
000308503 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2026
000308503 3367_ $$2DRIVER$$aarticle
000308503 3367_ $$2DataCite$$aOutput Types/Journal article
000308503 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769064951_2860948$$xLetter
000308503 3367_ $$2BibTeX$$aARTICLE
000308503 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000308503 3367_ $$00$$2EndNote$$aJournal Article
000308503 500__ $$a#EA:E270# / epub / Perspectives
000308503 520__ $$aProstate-specific membrane antigen (PSMA)-targeting strategies in prostate cancer have evolved rapidly from early antibody-based approaches to highly effective diagnostic and therapeutic agents. While PSMA remains a central benchmark in metastatic disease, biological heterogeneity and therapy resistance underscore the need for continued innovation and rational combination strategies.
000308503 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000308503 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000308503 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b1$$udkfz
000308503 7001_ $$aBabich, John W$$b2
000308503 773__ $$0PERI:(DE-600)1482253-2$$a10.1016/j.eururo.2026.01.002$$gp. S0302283826000035$$pnn$$tEuropean urology$$vnn$$x0302-2838$$y2026
000308503 8564_ $$uhttps://inrepo02.dkfz.de/record/308503/files/1-s2.0-S0302283826000035-main.pdf
000308503 8564_ $$uhttps://inrepo02.dkfz.de/record/308503/files/1-s2.0-S0302283826000035-main.pdf?subformat=pdfa$$xpdfa
000308503 909CO $$ooai:inrepo02.dkfz.de:308503$$pVDB
000308503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000308503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000308503 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000308503 9141_ $$y2026
000308503 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-20$$wger
000308503 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL : 2022$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000308503 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bEUR UROL : 2022$$d2024-12-20
000308503 9201_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000308503 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x1
000308503 9200_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000308503 980__ $$ajournal
000308503 980__ $$aVDB
000308503 980__ $$aI:(DE-He78)E270-20160331
000308503 980__ $$aI:(DE-He78)E060-20160331
000308503 980__ $$aUNRESTRICTED